Earnings Preview: Eli Lilly & Co

Jul.24.12 | About: Eli Lilly (LLY)

Eli Lilly & Co. (LLY) is scheduled to report its Q2 2012 results on July 25, 2012, before market opens. The street expects EPS and revenue of $0.76 and $5.58B, respectively.

In this article I will recap the historical results of the company, its latest EPS estimates vs. surprises, the latest news from LLY and the news from its closest competitors.

Eli Lilly & Co. Revenue and Net Income History

Recent EPS Actuals vs. Estimates

The company has met or beaten analysts' estimates in the last four quarters. In the last quarter it reported $0.92 EPS, beating analyst estimates of $0.78.

Eli Lilly & Co. EPS Historical Results vs Estimates

The consensus EPS estimate is $0.76 based on 17 analysts' estimates, down from $1.18 a year ago. Revenue estimates are $5.58B, down from $6.25B a year ago. The median target price by analysts for the stock is $39.00.

Average recommendation: Hold

Source: Marketwatch

Latest News

  • On July 11, 2012, Eli Lilly And Co announced negative clinical trial results from study H8Y-MC-HBBM (HBBM) investigating pomaglumetad methionil, also known as mGlu2/3, for the treatment of patients suffering an acute exacerbation of schizophrenia.
  • On July 7, 2012, Eli Lilly And Co and Bristol-Myers Squibb Co announced that ERBITUX (cetuximab) in combination with the chemotherapy regimen FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) has been granted full approval by the U.S. Food and Drug Administration (FDA) for the first-line treatment of patients with KRAS mutation-negative (commonly known as KRAS wild-type), epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC) as determined by FDA-approved tests for this use. ERBITUX is not indicated for the treatment of KRAS mutation-positive colorectal cancer.
  • On June 19, 2012, Eli Lilly And Co announced that it has declared a dividend for the third quarter of 2012 of $0.49 a share on outstanding common stock. The dividend is payable September 10, 2012 to shareholders of record at the close of business on August 15, 2012.
  • On June 12, 2012, Eli Lilly And Co announced an increase of its network of manufacturing capabilities in this key emerging market Country through an expanded collaboration with Novast Laboratories, LTD. Novast, a generic and specialty pharmaceutical company based in Nantong, China, has established high systems and manufacturing facilities for the global and domestic Chinese markets.
  • On June 11, 2012, Eli Lilly And Co and Incyte Corporation announced the presentation of 12-week results from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis (RA).
  • On June 9, 2012, Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Co presented results from two randomized phase 3 clinical trials and a post-hoc analysis for linagliptin at the American Diabetes Association's (ADA's) 72nd Scientific Sessions.
  • On June 9, 2012, Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Co announced results from a post-hoc analysis, which explored the clinical effect of linagliptin on albuminuria in patients with type 2 diabetes who had early diabetic nephropathy (renal disease).
  • On June 9, 2012, Boehringer Ingelheim and Eli Lilly and Co announced results from a post-hoc analysis that showed linagliptin is associated with improvements in glucose levels and a significant reduction in urinary albumin-to-creatinine ratio (UACR) of 33% (p
  • On June 9, 2012, Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Co presented results that showed empagliflozin (BI 10773), alone or as an add-on to metformin, reduced hemoglobin A1c (HbA1c or A1C) levels, fasting plasma glucose (FPG) levels and body weight when given to adults with type 2 diabetes for up to 90 weeks.
  • On May 31, 2012, Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company announced results of the PREVAIL U.S. study (Pitavastatin compaREd with praVAstatin In Lowering LDL-C in the U.S.) which evaluated the efficacy of LIVALO (pitavastatin) 4 mg compared with pravastatin 40 mg in reducing low-density lipoprotein cholesterol (LDL-C), the primary endpoint, as well as effects on other lipid parameters and lipoprotein particles in adult patients with primary hyperlipidemia or mixed dyslipidemia.
  • On April 25, 2012, Eli Lilly and Company raised its fiscal 2012 earnings per share (EPS) guidance and now expects fiscal 2012 earnings per share to be in the range of $3.14 to $3.29 on a reported basis and $3.15 to $3.30 on a non-GAAP basis.
  • On April 16, 2012, Eli Lilly and Company announced that its Board of Directors declared a dividend for the second quarter of 2012 of $0.49 a share on outstanding common stock.
  • On April 16, 2012, Vanda Pharmaceuticals Inc. announced that it has acquired an exclusive world-wide license from Eli Lilly and Company (Lilly) to develop and commercialize a small molecule neurokinin 1 receptor (NK-1R) antagonist for all human indications.
  • On April 7, 2012, Eli Lilly and Company and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, announced the U.S. Food and Drug Administration (FDA) approval of Amyvid, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline.
  • On March 23, 2012, Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced that the European Commission has granted marketing authorization to BYETTA as an adjunctive therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents.
  • On January 31, 2012, Eli Lilly and Company announced that for fiscal 2012, it anticipates revenue of between $21.8 and $22.8 billion. This includes an expected decline of over $3 billion in Zyprexa sales due to patent expirations in most markets outside of Japan.
  • On January 31, 2012, Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin.
  • On January 24, 2012, Eli Lilly and Company's Elanco announced that Lilly has signed an agreement to acquire ChemGen Corp., a privately held bioscience company specializing in the development and commercialization of feed enzyme products that improve the efficiency of poultry, egg, and meat production.

Competitors

AstraZeneca (AZN), Bristol-Myers Squibb (BMY), GlaxoSmithKline (GSK), Pfizer (PFE), and Sanofi (SNY) are considered major competitors for Eli Lilly and the table below provides the key metrics for these companies and the industry.

Eli Lilly & Co. key ratio comparison with direct competitors

The chart below compares the stock price changes as a percentage for the selected companies for the last one year period.

LLY ChartClick to enlarge

LLY data by YCharts

Competitors' Latest Development

  • On July 20, 2012, Sanofi SA and Regeneron Pharmaceuticals Inc announced that several trials within ODYSSEY, the Phase 3 clinical program of SAR236553/REGN727, have initiated patient enrollment.
  • On July 19, 2012, Pfizer Inc announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for postmenopausal women with a uterus for the treatment of estrogen deficiency symptoms and treatment of osteoporosis in women at risk of fracture.
  • On July 19, 2012, Pfizer Inc. announced that the United States District Court for the District of Delaware upheld its composition of matter patent and pain and seizure use patents covering LYRICA (pregabalin) capsules CV. With this decision, Pfizer will exclusively provide pregabalin as LYRICA to patients through December 30, 2018 in the U.S., pending generic company appeal and further litigation.
  • On July 18, 2012, Sanofi SA announced a new research collaboration with Brigham and Women's Hospital (BWH), a teaching and research affiliate of Harvard Medical School, focused on immunology of type 1 diabetes.
  • On July 17, 2012, AstraZeneca PLC announced that it plans to conduct the EUCLID study, a global clinical trial involving 11,500 patients with peripheral artery disease (PAD), a condition affecting approximately 27 million people in Europe and North America.1 PAD patients are at high risk of myocardial infarction (MI), strokes, and other health complications.
  • On July 16, 2012, Reuters reported that Glaxosmithkline Plc is expected to announce an agreement to acquire Human Genome Sciences Inc for about $2.8 billion as soon as Monday, ending three months of its hostile pursuit of the U.S. biotechnology company.
  • On July 16, 2012, Glaxosmithkline Plc and Human Genome Sciences announced that the companies have entered into a definitive agreement under which GSK will acquire HGS for USD14.25 per share in cash.
  • On July 13, 2012, The Wall Street Journal reported that Sanofi SA is considering the possible elimination of several thousand jobs in France, Industry Minister Arnaud Montebourg said Thursday, after the company lost patent protection in the U.S. on some of its drugs earlier this year.
  • On July 12, 2012, AstraZeneca PLC announced that it has acquired a portfolio of neuroscience assets from Link Medicine Corporation, a privately held biopharmaceutical company based in Massachusetts, USA. Link Medicine has focused its research and development efforts in the field of autophagy, an intracellular process that clears and recycles misfolded proteins and has been developing potential new treatments for a range of neurodegenerative diseases.
  • On July 12, 2012, AstraZeneca PLC and Dr. Steven Paul of Weill Cornell Medical College announced a first of its kind research alliance that brings four leading academic research laboratories together with AstraZeneca to study a major risk factor for Alzheimer's disease, the apolipoprotein E4 genotype (ApoE).
  • On July 9, 2012, Reuters reported that Sanofi SA has withdrawn its application to sell Mulsevo, an experimental drug to prevent blood clots in chemotherapy patients, in the European Union after it failed to win the backing of the U.S. regulator last month.
  • On July 7, 2012, Eli Lilly And Co and Bristol-Myers Squibb Co announced that ERBITUX (cetuximab) in combination with the chemotherapy regimen FOLFIRI (irinotecan, 5-fluorouracil, leucovorin) has been granted full approval by the U.S. Food and Drug Administration (FDA) for the first-line treatment of patients with KRAS mutation-negative (commonly known as KRAS wild-type), epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC) as determined by FDA-approved tests for this use. ERBITUX is not indicated for the treatment of KRAS mutation-positive colorectal cancer.
  • On July 6, 2012, Reuters reported that Five big U.S. retailers filed an antitrust lawsuit against Pfizer Inc and India's Ranbaxy Laboratories Ltd, accusing them of conspiring to delay sales of generic versions of Lipitor.
  • On July 5, 2012, Reuters reported that Sanofi SA plans to cut 1,000 to 2,000 jobs in France, according to French daily Le Figaro, the latest in a series of cost-cutting moves at the Company, some of whose key drugs face increased competition from generic rivals.
  • On July 4, 2012, Reuters reported that Nestle SA has signed a $8.5 billion syndicated bridge loan to back its $11.85 billion takeover of Pfizer, Inc.'s infant nutrition business.
  • On July 4, 2012, Sanofi SA announced the execution of an agreement pursuant to which Sanofi will divest its direct and indirect stake of approximately 19.3% in the Yves Rocher Group to Societe Financiere des Laboratoires de Cosmetologie Yves Rocher, subject to certain closing conditions.
  • On July 2, 2012, AstraZeneca PLC And Cellworks announced a collaboration supported by the Wellcome Trust to speed the design of combination therapies for the treatment of drug-sensitive and resistant tuberculosis.
  • On July 2, 2012, Reuters reported that Bristol-Myers Squibb Co will buy biotechnology company Amylin Pharmaceuticals Inc for about $5.3 billion in cash. Bristol-Myers said late on Friday it had also reached a follow-on deal with UK-based AstraZeneca PLC to collaborate on developing Amylin's products once the buyout is completed, expanding upon an existing partnership between the two pharmaceutical makers in diabetes treatments.
  • On July 2, 2012, Glaxosmithkline Plc and Theravance, Inc. announced the results of four pivotal phase III studies of investigational LAMA/LABA involving over 4,000 patients with chronic obstructive pulmonary disease (COPD).
  • On July 2, 2012, GlaxoSmithKline plc announced that it has reached an agreement with the US Government, multiple states and the District of Columbia to conclude GSK's most significant ongoing Federal government investigations.
  • On June 29, 2012, Glaxosmithkline Plc announced it has extended its tender offer to acquire all of the outstanding shares of Human Genome Sciences for USD13.00 per share in cash to 5:00 p.m New York City time on July 20, 2012.
  • On June 29, 2012, Human Genome Sciences Inc (HGS) announced statement regarding the extension by GlaxoSmithKline plc of unsolicited tender offer to acquire all the outstanding common shares of HGS at a price of $13.00 per share in cash and GSK's statement that approximately 375,526 shares of HGS common stock have been tendered into their offer.
  • On June 29, 2012, Medivir AB announced that a phase II combination study with the investigational compound TMC435 and Bristol-Myers Squibb Co.'s investigational compound daclatasvir will start in July 2012.
  • On June 29, 2012, Pfizer Inc announced that its Board of Directors declared a $0.22 third-quarter 2012 dividend on the Company`s common stock, payable September 5, 2012, to shareholders of record at the close of business on August 3, 2012.
  • On June 28, 2012, Breckenridge Pharmaceutical, Inc. announced that Breckenridge and Alembic Pharmaceuticals Limited were named codefendants in a Paragraph IV lawsuit filed by Pfizer Inc. concerning their ANDA desvenlafaxine succinate extended-release tablets 50mg and 100mg, a generic version of Pristiq by Pfizer Inc. Breckenridge and Alembic filed their Paragraph IV ANDA on the first-possible submission date and expects to share 180-day exclusivity with other ANDA first filers.
  • On June 28, 2012, Reuters reported that Nestle SA has been talking to banks about raising a new EUR7 billion ($8.7 billion) syndicated loan to help fund its $11.85 billion takeover of Pfizer, Inc.'s Nutrition.
  • On June 27, 2012, Merck & Co Inc, known as MSD outside the United States and Canada announced that Merck and AstraZeneca PLC have amended the option agreement related to their partnership known as AstraZeneca LP (AZLP).
  • On June 26, 2012, Reuters reported that five pharmaceutical giants including Novartis AG and Sanofi SA remain in the running for Amylin Pharmaceuticals Inc, as the auction of the diabetes drug maker with a market value of $4.5 billion enters the last leg, according to people familiar with the matter.
  • On June 26, 2012, Bristol-Myers Squibb Co announced that its Board of Directors declared a quarterly dividend of $0.34 per share on the $0.10 par value Common Stock of the corporation.
  • On June 26, 2012, Reuters reported that five pharmaceutical giants including Novartis AG and Sanofi SA remain in the running for Amylin Pharmaceuticals Inc, as the auction of the diabetes drug maker with a market value of $4.5 billion enters the last leg, according to people familiar with the matter.
  • On June 25, 2012, Bristol-Myers Squibb Co and Pfizer, Inc. announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for ELIQUIS (apixaban) for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
  • On June 22, 2012, AstraZeneca PLC announced that the Committee for Medicinal Products for Human Use (OTCQB:CHMP) has adopted a positive opinion, recommending the approval of Zinforo (ceftaroline fosamil), a new intravenous cephalosporin antibiotic for the treatment of adult patients with complicated Skin and Soft Tissue Infections (cSSTI) or Community Acquired Pneumonia (CAP).
  • On June 22, 2012, Pfizer Inc and Protalix BioTherapeutics, Inc. announced that the European Medicines Agency 's Committee for Medicinal Products for Human Use has adopted an Opinion recommending against the Marketing Authorization of taliglucerase alfa, an enzyme replacement therapy (ERT) for the treatment of Gaucher disease.
  • On June 22, 2012, Sanofi SA announced that Sanofi Pasteur's vaccine Hexaxim (DTCa-IPV-Hib-HepB) received a positive opinion from the European Medicaments Agency as part of a special procedure to evaluate health products destined for sale outside the European Union.
  • On June 21, 2012, Pfizer Inc announced that the U.S. Food and Drug Administration (FDA) approved the use of Lyrica (pregabalin) capsules CV for the management of neuropathic pain associated with spinal cord injury.
  • On June 20, 2012, AstraZeneca PLC announced that it has on June 19, 2012 completed acquisition of Ardea Biosciences Inc (Ardea), a biotechnology company in San Diego, California.
  • On June 20, 2012, Bristol-Myers Squibb Co and Emory University announced the formation of a strategic partnership to conduct clinical trials involving Bristol-Myers Squibb's investigational compounds.
  • On June 20, 2012, Reuters reported that Sanofi SA failed to win a U.S. advisory panel's support for an injection meant to prevent blood clots in certain cancer patients, making it unlikely the drug will be approved in the United States.
  • On June 19, 2012, AstraZeneca PLC and Rigel Pharmaceuticals Inc announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signaling, which is being investigated as a treatment for moderate to severe chronic asthma.
  • On June 19, 2012, KineMed Inc announced that it is to take part in a multiannual research and development program with Glaxosmithkline Plc which will use KineMed Inc's platform to discover biomarkers in therapeutic areas which are of interest to Glaxosmithkline Plc.
  • On June 19, 2012, Reuters reported that Glaxosmithkline Plc and Novartis AG will get federal money to help develop medicines against pandemics and bioterrorist threats.
  • On June 19, 2012, Palatin Technologies Inc announced that a Phase I clinical trial being conducted by AstraZeneca PLC of AZD2820, a subcutaneously-administered peptide melanocortin-4 receptor partial agonist under development for the treatment of obesity, has been halted.
  • On June 19, 2012, Pfizer Inc announced that the PROFILE 1007 study met its primary endpoint, demonstrating that XALKORI (crizotinib) significantly improved progression-free survival (PFS) when compared with pemetrexed or docetaxel, in previously treated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
  • On June 19, 2012, Sanofi SA and the Joslin Diabetes Center, a teaching and research affiliate of Harvard Medical School, announced a new collaboration to promote the development of new medicines for the treatment of diabetes and related disorders.
  • On June 18, 2012, Reuters reported that U.S. health regulators declined to approve a Pfizer Inc's drug for a rare and fatal neurodegenerative disease until a second study can establish the effectiveness of the treatment.
  • On June 18, 2012, Reuters reported that Takeda Pharmaceutical Company Limited will stop distributing 13 Pfizer, Inc. drugs it now sells in Japan at the end of this year and Pfizer itself will begin selling them from 2013.
  • On June 18, 2012, Reuters reported that the supreme court ruled on Jun 18, 2012 that pharmaceutical companies do not have to pay overtime to their representatives who visit doctors' offices to promote their products, a dispute that had threatened the industry with billions of dollars in potential liability.
  • On June 15, 2012, GlaxoSmithKline plc announced that it has received a renewed invitation from Human Genome Sciences Inc' to participate in its strategic alternatives review process which started in April.
  • On June 15, 2012, Glaxosmithkline Plc announced that the U.S. Food and Drug Administration (FDA) has approved the vaccine MenHibrix [Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine].
  • On June 13, 2012, Reuters reported that CVS Caremark Corporation and Rite Aid Corporation filed an antitrust lawsuit accusing Pfizer Inc and Teva Pharmaceutical Industries Ltd of conspiring to keep generic versions of antidepressant Effexor XR off store shelves.
  • On June 12, 2012, Stiefel, a Glaxosmithkline Plc company announced that it has entered into a worldwide agreement to acquire Toctino (alitretinoin) from Basilea Pharmaceutica Ltd. (Basilea).
  • On June 12, 2012, Genzyme, a Sanofi SA company, announced that the company has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a marketing authorization application to the European Medicines Agency seeking approval of LEMTRADA (alemtuzumab) for treatment of relapsing multiple sclerosis (RMS).
  • On June 11, 2012, Zealand Pharma A/S announced that its partner Sanofi SA announced data demonstrating that Lyxumia (lixisenatide), a once-daily investigational GLP-1 agonist, in combination with basal insulin plus oral anti-diabetic agents (OADs), significantly reduced HbA1c - glycated hemoglobin - in people with type 2 diabetes who were either new to insulin therapy (as early as 12 weeks after initiation) or already treated with insulin (for an average of 3.1 years).
  • On June 9, 2012, Bristol-Myers Squibb Co and AstraZeneca PLC announced results from a Phase 3 clinical study that showed the investigational compound dapagliflozin 10 mg demonstrated significant reductions in blood sugar levels (glycosylated hemoglobin levels, or HbA1c) compared with placebo at 24 weeks when either agent was added to existing sitagliptin therapy (with or without metformin) in adult patients with type 2 diabetes.
  • On June 9, 2012, Glaxosmithkline Plc announced that detailed findings from a Phase III study comparing the investigational glucagon-like peptide-1 (GLP-1) receptor agonist albiglutide to prandial insulin (Lispro), were presented at the American Diabetes Association Meeting (ADA) in Philadelphia, USA, and show that the effect is maintained out to 52 weeks.
  • On June 9, 2012, Sanofi SA announced that people with early type 2 diabetes uncontrolled on metformin demonstrated superior HbA1c -- glycated hemoglobin -- reduction with Lantus(R) (insulin glargine [rDNA origin] injection) versus sitagliptin.
  • On June 7, 2012, Glaxosmithkline Plc and XenoPort, Inc. announced that the United States (US) Food and Drug Administration (FDA) has approved Horizant (gabapentin enacarbil) Extended-Release Tablets for the management of postherpetic neuralgia (PHN) in adults.
  • On June 7, 2012, Pfizer Inc announced the next steps in the strategic alternatives review process for the Company's Animal Health business. Preparations are underway to file a registration statement in the U.S. for a potential initial public offering (NYSEARCA:IPO) of a minority ownership stake in the new company.
  • On June 6, 2012, Bristol-Myers Squibb Co announced the results of AMPLE (Abatacept Versus Adalimumab Comparison in Biologic-Naïve rheumatoid arthritis Subjects With Background Methotrexate), a head-to-head clinical trial of 646 patients comparing the subcutaneous (SC) formulation of ORENCIA (abatacept) vs. Humira (adalimumab), each on a background of methotrexate (MTX), in biologic naïve patients with moderate to severe RA. AMPLE met its primary endpoint (as measured by non-inferiority) and demonstrated that ORENCIA plus MTX achieved comparable rates of efficacy for the American College of Rheumatology criteria of 20% (ACR20) response at one year of 64.8% vs. 63.4% Humira plus MTX. ACR50, 70 and major clinical response (ACR70 for 6 consecutive months), considered to be more stringent measures of efficacy, as well as DAS-28-CRP, were also assessed at one year and found to be generally comparable for the two arms.
  • On June 6, 2012, Reuters reported that Pfizer Inc will cut 177 jobs in Ireland following the expiration of patents on blockbuster cholesterol drug Lipitor, highlighting the exposure of Ireland's export-driven economy to the patent cliff facing many in the pharmaceutical sector.
  • On June 6, 2012, Sanofi SA announced that it expects sales to grow but at least-by at least 5%.
  • On June 4, 2012, Reuters reported that AstraZeneca PLC and Bristol-Myers Squibb Co are among several pharmaceutical companies that have submitted initial bids for Amylin Pharmaceuticals Inc the diabetes drugmaker that is exploring a sale.
  • On June 4, 2012, Reuters reported that late stage trials of two experimental skin cancer drugs from Glaxosmithkline Plc, each designed to block different pathways used by tumor cells, have found the drugs helped patients with fewer side effects than current chemotherapy.
  • On June 2, 2012, Bristol-Myers Squibb Co. announced interim results from the expanded Phase 1 dose-ranging study 003 (n=296) of its investigational anti-PD-1 immunotherapy (BMS-936558), which showed clinical activity in patients with previously-treated non small-cell lung cancer (NSCLC), metastatic melanoma and renal cell carcinoma (RCC).
  • On June 1, 2012, Sanofi SA and its subsidiary Genzyme announced top-line results from the TOWER (Teriflunomide Oral in people With relapsing remitting multiplE scleRosis) trial that assessed the efficacy and safety of once-daily, oral teriflunomide in patients with relapsing forms of multiple sclerosis (MS).
  • On May 30, 2012, Welichem Biotech Inc. and Stiefel, a Glaxosmithkline Plc company announced that they have entered into an agreement for the acquisition by Stiefel of exclusive development and commercialization rights to the novel anti-inflammatory agent, WBI-1001, in all territories in the world outside of China, Taiwan, Macao and Hong Kong.
  • On May 25, 2012, Reuters reported that Pfizer Inc said a U.S. health advisory panel voted against its drug to treat a rare neurodegenerative disease as the data did not show enough evidence of efficacy.
  • On May 22, 2012, Reuters reported that U.S. drug reviewers on Tuesday recommended rejecting a Pfizer Inc drug because the data did not prove it worked well in treating a rare neurodegenerative disease.
  • On May 18, 2012, Pfizer Inc announced the results of studies on Lyrica (pregabalin) capsules CV presented at the American Pain Society Annual Meeting in Honolulu. The studies included exploratory research designed to provide new insight into how Lyrica works in the brains of patients with fibromyalgia.
  • On May 9, 2012, Reuters reported that Pfizer Inc won support from a U.S. advisory panel on Wednesday for its arthritis drug. A panel of outside experts to the U.S. Food and Drug Administration voted 8-2 to recommend approval of tofacitinib, a treatment for patients with rheumatoid arthritis who have not had success with at least one other drug for the disease.
  • On May 7, 2012, Astellas Pharma Inc. announced that the United States District Court for the District of Delaware found both the patents in a suit brought against Mylan Pharmaceuticals Inc. to be valid and entered judgment in favor of OSI Pharmaceuticals, LLC (a United States-based affiliate of Astellas), Genentech, Inc., and Pfizer Inc.On March 19, 2009, Genentech Inc.,, OSI Pharmaceuticals, and Pfizer Inc., filed a patent infringement lawsuit in the United States District Court in Delaware against Mylan for infringement of United States Patent Nos.5747498 (reissued as RE 41065) and 6900221, which cover Tarceva (erlotinib) tablets and their use.
  • On May 2, 2012, Pfizer Inc And Protalix BioTherapeutics Inc. announced that the United States (U.S.) Food and Drug Administration (FDA) approved ELELYSO (taliglucerase alfa) for injection, an enzyme replacement therapy for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease.
  • On April 27, 2012, Sanofi SA announced that the Company is optimistic to achieve another record sales for the first half of 2012 in total.
  • On April 26, 2012, Bristol-Myers Squibb Co. announced that for fiscal 2012, it confirms GAAP and non-GAAP EPS guidance range of $1.90 to $2.00. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report EPS of $1.97 for fiscal 2012.
  • On April 26, 2012, Pfizer Inc announced that the Board OF Directors of the Company declared a $0.22 second-quarter 2012 dividend on the Company's common stock, payable June 5, 2012, to shareholders of record at the close of business on May 11, 2012.
  • On April 24, 2012, Reuters reported that Nestle SA may sell about 10% to 15% of the $11.9 billion baby food business it is buying from Pfizer Inc to address antitrust concerns.
  • On April 23, 2012, Pfizer Inc announced that it has entered into an agreement to divest its Nutrition business to Nestle SA for $11.85 billion in cash. Pfizer Nutrition is a global pediatric nutrition company with a portfolio of brands encompassing everyday and specialty infant and toddler formulas, follow-on formulas, as well as maternal and adult nutrition products.

Technical Overview


The stock has a market capitalization of $51.26B and is currently trading at $44.17 with a 52 week range of $33.75 - $44.67. The stock's year-to-date performance has been 8.90%. It is currently trading above 20, 50 and 200 SMA.

Sources: Yahoo Finance, Google Finance, Marketwatch, Finviz, Reuters.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.